分子診断市場は、予測期間中に13.5%のCAGRで成長し、2024年の173億ドルから2029年には327億ドルに成長すると予想されます。この市場で活動している主要なプレーヤーは、Danaher(米国)、F. Hoffmann-La Roche Ltd.(スイス)、Illumina、Inc.(米国)、bioMérieux(フランス)、Hologic、Inc.(米国)、Abbott(米国)、Thermo Fisher Scientific Inc.(米国)、QIAGEN(オランダ)、Revvity(米国)、Myriad Genetics、Inc.(米国)、Siemens Healthineers AG(ドイツ)、Becton、Dickinson and Company(米国)、Grifols、S.A.(スペイン)、QuidelOrtho Corporation(米国)、DiaSorin S.p.A.(イタリア)、 Exact Sciences Corporation(米国)、Genetic Signatures(オーストラリア)、Agilent Technologies, Inc.(米国)、MDxHealth(ベルギー)、Biocartis(ベルギー)、TBG Diagnostics Limited(オーストラリア)、HTG Molecular Diagnostics, Inc.(米国)、Vela Diagnostics(シンガポール)、Amoy Diagnostics Co., Ltd.(中国)、ELITechGroup(フランス)、Molbio Diagnostics Pvt. Ltd.(インド)、geneOmbio Technologies(インド)、Savyon Diagnostics(イスラエル)、Uniogen OY(フィンランド)。
目次
TABLE OF CONTENTS
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS (Page No. - 53)
4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW
4.2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028
4.3 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2028
4.4 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028
4.5 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028
4.6 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028
4.7 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028
4.8 MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
5 MARKET OVERVIEW (Page No. - 57)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of infectious diseases and cancer globally
5.2.1.2 Rising focus on R&D and growing funding in molecular diagnostics by healthcare-based companies
5.2.1.3 Growing awareness regarding early disease diagnosis in developing countries
5.2.1.4 Rising technological advancements in molecular diagnostics in recent years
5.2.1.5 Increasing use of PoC diagnostic tests in homecare settings and hospitals
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario for diagnostic companies
5.2.2.2 High cost of molecular diagnostic instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Growing significance of companion diagnostics in drug development process
5.2.3.2 Increasing growth opportunities for molecular diagnostics companies in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Changing regulatory landscape for IVD and molecular diagnostics in US and European Union
5.2.4.2 Operational barriers and shortage of skills across major markets
5.2.4.3 Introduction of alternative technologies for disease detection and diagnosis
5.3 PRICING ANALYSIS
5.3.1 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTICS PRODUCTS, BY KEY PLAYER
5.4 PATENT ANALYSIS
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM/MARKET MAP ANALYSIS
5.7.1 MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT FROM NEW ENTRANTS
5.8.2 THREAT FROM SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 REGULATORY ANALYSIS
5.9.1 NORTH AMERICA
5.9.1.1 US
5.9.1.2 Canada
5.9.2 EUROPE
5.9.3 ASIA PACIFIC
5.9.3.1 China
5.9.3.2 Japan
5.9.3.3 India
5.9.4 LATIN AMERICA
5.9.4.1 Brazil
5.9.4.2 Mexico
5.9.5 MIDDLE EAST
5.9.6 AFRICA
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
5.10.1.1 Import data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million)
5.10.1.2 Export data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million)
5.11 TECHNOLOGY ANALYSIS
5.12 KEY CONFERENCES AND EVENTS IN 2023-2024
5.13 PESTLE ANALYSIS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.14.1 REVENUE SHIFT IN MOLECULAR DIAGNOSTICS MARKET
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.15.2 BUYING CRITERIA
5.16 CASE STUDY ANALYSIS
6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 88)
6.1 INTRODUCTION
6.2 REAGENTS & KITS
6.2.1 RECURRENT PURCHASES OF REAGENTS & KITS FOR DIAGNOSTIC ANALYSIS TO PROPEL MARKET
6.3 INSTRUMENTS
6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST MARKET
6.4 SERVICES & SOFTWARE
6.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET TO DRIVE GROWTH
7 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE (Page No. - 95)
7.1 INTRODUCTION
7.1.1 PRIMARY NOTES
7.1.1.1 Key industry insights
7.2 LAB TESTS
7.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET
7.3 POC TESTS
7.3.1 FASTER TURNAROUND TIME OF POC TESTS TO DRIVE SEGMENT GROWTH
8 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE (Page No. - 100)
8.1 INTRODUCTION
8.2 BLOOD, SERUM, AND PLASMA
8.2.1 UTILIZATION OF BLOOD SAMPLES IN DETECTING AND MANAGING INFECTIOUS DISEASES TO DRIVE MARKET
8.3 URINE
8.3.1 NON-INVASIVE NATURE OF URINE SAMPLES TO FUEL SEGMENT GROWTH
8.4 OTHER SAMPLE TYPES
9 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 104)
9.1 INTRODUCTION
9.1.1 PRIMARY NOTES
9.1.1.1 Key industry insights
9.2 POLYMERASE CHAIN REACTION
9.2.1 GROWING USE OF POLYMERASE CHAIN REACTION IN PROTEOMICS AND GENOMICS TO DRIVE MARKET
9.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
9.3.1 COST BENEFITS OF ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY IN NUCLEIC ACID SEQUENCING TO DRIVE MARKET
9.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
9.4.1 INCREASING USE OF NEXT-GENERATION SEQUENCING IN CANCER DIAGNOSIS TO FUEL MARKET
9.5 IN SITU HYBRIDIZATION
9.5.1 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO DRIVE MARKET
9.6 DNA MICROARRAYS
9.6.1 INTRODUCTION OF DNA MICROARRAYS TO ACCELERATE GENE EXPRESSION AND DISEASE DIAGNOSIS
9.7 OTHER TECHNOLOGIES
10 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 114)
10.1 INTRODUCTION
10.2 INFECTIOUS DISEASE DIAGNOSTICS
10.2.1 HEPATITIS
10.2.1.1 Increasing adoption of advanced technologies for diagnosis of hepatitis B to drive segment
10.2.2 HIV
10.2.2.1 Increased global prevalence of HIV to propel segment
10.2.3 CT/NG
10.2.3.1 CT/NG infections to be most common sexually transmitted disease globally
10.2.4 HAIS
10.2.4.1 Rising burden of MRSA infections and increasing adoption of technologically advanced HAI diagnostic tests to aid market
10.2.5 HPV
10.2.5.1 Technological advancements for preventing HPV infections to augment market
10.2.6 TUBERCULOSIS
10.2.6.1 Increasing burden of tuberculosis globally to propel market
10.2.7 INFLUENZA
10.2.7.1 Rising focus on decreasing spread of influenza to propel segment
10.2.8 OTHER INFECTIOUS DISEASES
10.3 ONCOLOGY TESTING
10.3.1 BREAST CANCER
10.3.1.1 Increasing prevalence of breast cancer among females to boost market
10.3.2 COLORECTAL CANCER
10.3.2.1 Rising focus on development of companion diagnostic assays to fuel market
10.3.3 LUNG CANCER
10.3.3.1 Increasing research for lung cancer biomarkers to drive market
10.3.4 PROSTATE CANCER
10.3.4.1 Advancements in genomic technologies for development of new biomarkers to aid market
10.3.5 OTHER CANCERS
10.4 GENETIC TESTING
10.4.1 DIAGNOSIS OF VARIOUS DISEASES THROUGH GENETIC TESTING METHODS TO PROPEL MARKET
10.5 OTHER APPLICATIONS
10.6 COVID-19
10.6.1 DECLINING CASES OF COVID-19 TO HINDER MARKET
11 MOLECULAR DIAGNOSTICS MARKET, BY END USER (Page No. - 136)
11.1 INTRODUCTION
11.2 DIAGNOSTIC LABORATORIES
11.2.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR REDUCTION IN COSTS TO DRIVE MARKET
11.3 HOSPITALS & CLINICS
11.3.1 GREATER NUMBER OF HOSPITALS AND HIGHER GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST SEGMENT
11.4 OTHER END USERS
12 MOLECULAR DIAGNOSTICS MARKET, BY REGION (Page No. - 141)
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA
12.2.2 US
12.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market
12.2.3 CANADA
12.2.3.1 High availability of funding for genomics research to fuel market
12.3 EUROPE
12.3.1 IMPACT OF ECONOMIC RECESSION ON EUROPE
12.3.2 GERMANY
12.3.2.1 Increasing healthcare expenditure with favorable government policies and rising per capita disposable income to propel market
12.3.3 UK
12.3.3.1 Growing number of accredited diagnostic laboratories to fuel market
12.3.4 FRANCE
12.3.4.1 Rising R&D expenditure and increasing demand for early disease diagnosis to augment market
12.3.5 ITALY
12.3.5.1 Adoption of advanced diagnostic technologies to support market
12.3.6 SPAIN
12.3.6.1 Growing demand for genetic testing to create major growth opportunities for market players
12.3.7 RUSSIA
12.3.7.1 Increasing access to quality healthcare and growing incidence of infectious diseases to aid market
12.3.8 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Rapid economic growth and greater public access to modern healthcare to drive market
12.4.3 JAPAN
12.4.3.1 Universal healthcare reimbursement policy to support market
12.4.4 INDIA
12.4.4.1 Increased private & public investments and large patient population to drive market
12.4.5 AUSTRALIA
12.4.5.1 High prevalence of infectious diseases to fuel market
12.4.6 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 IMPACT OF ECONOMIC RECESSION ON LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Improving healthcare infrastructure and stringent regulations to fuel market
12.5.3 MEXICO
12.5.3.1 Improving accessibility and affordability of healthcare services to aid market
12.5.4 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
12.6.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED HEALTHCARE INVESTMENTS TO PROPEL MARKET
12.6.2 IMPACT OF ECONOMIC RECESSION ON MIDDLE EAST & AFRICA
13 COMPETITIVE LANDSCAPE (Page No. - 219)
13.1 OVERVIEW
13.2 STRATEGIES ADOPTED BY KEY PLAYERS
13.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
13.4 MARKET SHARE ANALYSIS
13.4.1 MOLECULAR DIAGNOSTICS MARKET SHARE AND RANKING ANALYSIS, BY TECHNOLOGY
13.4.1.1 Polymerase chain reaction (PCR)
13.4.1.2 DNA sequencing and NGS
13.4.1.3 Isothermal nucleic acid amplification technology (INAAT)
13.4.1.4 In situ hybridization (ISH)
13.4.2 MOLECULAR DIAGNOSTICS MARKET RANKING ANALYSIS, BY APPLICATION
13.4.2.1 Infectious diseases
13.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS
13.5.1 LIST OF EVALUATED VENDORS
13.5.2 STARS
13.5.3 EMERGING LEADERS
13.5.4 PERVASIVE PLAYERS
13.5.5 PARTICIPANTS
13.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022)
13.6.1 PROGRESSIVE COMPANIES
13.6.2 STARTING BLOCKS
13.6.3 RESPONSIVE COMPANIES
13.6.4 DYNAMIC COMPANIES
13.7 COMPETITIVE BENCHMARKING
13.7.1 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS
13.8 COMPETITIVE SCENARIO
13.8.1 KEY PRODUCT LAUNCHES
13.8.2 KEY DEALS
14 COMPANY PROFILES (Page No. - 235)
14.1 KEY PLAYERS
14.1.1 DANAHER
14.1.1.1 Business overview
14.1.1.2 Products/Services/Solutions offered
14.1.1.3 Recent developments
14.1.1.4 MnM view
14.1.1.4.1 Right to win
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses and competitive threats
14.1.2 F. HOFFMANN-LA ROCHE LTD.
14.1.2.1 Business overview
14.1.2.2 Products/Services/Solutions offered
14.1.2.3 Recent developments
14.1.2.4 MnM view
14.1.2.4.1 Right to win
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses and competitive threats
14.1.3 HOLOGIC, INC.
14.1.3.1 Business overview
14.1.3.2 Products/Services/Solutions offered
14.1.3.3 Recent developments
14.1.3.4 MnM view
14.1.3.4.1 Right to win
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses and competitive threats
14.1.4 ILLUMINA, INC.
14.1.4.1 Business overview
14.1.4.2 Products/Services/Solutions offered
14.1.4.3 Recent developments
14.1.4.4 MnM view
14.1.4.4.1 Right to win
14.1.4.4.2 Strategic choices
14.1.4.4.3 Weaknesses and competitive threats
14.1.5 ABBOTT LABORATORIES
14.1.5.1 Business overview
14.1.5.2 Products/Services/Solutions offered
14.1.5.3 Recent developments
14.1.5.4 MnM view
14.1.5.4.1 Right to win
14.1.5.4.2 Strategic choices
14.1.5.4.3 Weaknesses and competitive threats
14.1.6 BIOMÉRIEUX
14.1.6.1 Business overview
14.1.6.2 Products/Services/Solutions offered
14.1.6.3 Recent developments
14.1.7 THERMO FISHER SCIENTIFIC INC.
14.1.7.1 Business overview
14.1.7.2 Products/Services/Solutions offered
14.1.7.3 Recent developments
14.1.8 QIAGEN
14.1.8.1 Business overview
14.1.8.2 Products/Services/Solutions offered
14.1.8.3 Recent developments
14.1.9 REVVITY
14.1.9.1 Business overview
14.1.9.2 Products/Services/Solutions offered
14.1.9.3 Recent developments
14.1.10 MYRIAD GENETICS, INC.
14.1.10.1 Business overview
14.1.10.2 Products/Services/Solutions offered
14.1.10.3 Recent developments
14.1.11 SIEMENS HEALTHINEERS AG
14.1.11.1 Business overview
14.1.11.2 Products/Services/Solutions offered
14.1.11.3 Recent developments
14.2 OTHER PLAYERS
14.2.1 BECTON, DICKINSON AND COMPANY
14.2.2 GRIFOLS, S.A.
14.2.3 QUIDELORTHO CORPORATION
14.2.4 AGILENT TECHNOLOGIES, INC.
14.2.5 DIASORIN S.P.A.
14.2.6 EXACT SCIENCES CORPORATION
14.2.7 GENETIC SIGNATURES
14.2.8 MDXHEALTH
14.2.9 HTG MOLECULAR DIAGNOSTICS, INC.
14.2.10 BIOCARTIS
14.2.11 TBG DIAGNOSTICS LIMITED
14.2.12 VELA DIAGNOSTICS
14.2.13 AMOY DIAGNOSTICS CO., LTD.
14.2.14 ELITECHGROUP
14.2.15 MOLBIO DIAGNOSTICS PVT. LTD.
14.2.16 SAVYON DIAGNOSTICS
14.2.17 ABACUS DIAGNOSTICA OY
14.2.18 GENEOMBIO TECHNOLOGIES PVT. LTD.
15 APPENDIX (Page No. - 307)
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
LIST OF TABLES (241 TABLES)
TABLE 1 ESTIMATED NUMBER OF NEW CANCER CASES GLOBALLY, BY TYPE OF CANCER, 2020 VS. 2025
TABLE 2 GLOBAL CANCER INCIDENCE, BY REGION, 2020 VS. 2025
TABLE 3 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS
TABLE 4 MOLECULAR DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 EUROPE: CLASSIFICATION OF DEVICES
TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 11 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023-2024
TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS (%)
TABLE 13 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS
TABLE 14 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 15 PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS (2022)
TABLE 16 MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION, 2021-2028 (USD MILLION)
TABLE 17 KEY INSTRUMENTS AVAILABLE IN GLOBAL MARKET
TABLE 18 MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)
TABLE 19 MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY REGION, 2021-2028 (USD MILLION)
TABLE 20 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
TABLE 21 MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY REGION, 2021-2028 (USD MILLION)
TABLE 22 MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY REGION, 2021-2028 (USD MILLION)
TABLE 23 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 24 MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2021-2028 (USD MILLION)
TABLE 25 MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY REGION, 2021-2028 (USD MILLION)
TABLE 26 MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021-2028 (USD MILLION)
TABLE 27 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 28 MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021-2028 (USD MILLION)
TABLE 29 MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2021-2028 (USD MILLION)
TABLE 30 MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2021-2028 (USD MILLION)
TABLE 31 MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION)
TABLE 32 MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2021-2028 (USD MILLION)
TABLE 33 MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION)
TABLE 34 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 35 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)
TABLE 36 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 37 HEPATITIS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 38 HEPATITIS MARKET, BY REGION, 2021-2028 (MILLION TESTS)
TABLE 39 HIV MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 40 HIV MARKET, BY REGION, 2021-2028 (MILLION TESTS)
TABLE 41 CT/NG MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 42 CT/NG MARKET, BY REGION, 2021-2028 (MILLION TESTS)
TABLE 43 HAIS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 44 HAIS MARKET, BY REGION, 2021-2028 (MILLION TESTS)
TABLE 45 HPV MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 46 HPV MARKET, BY REGION, 2021-2028 (MILLION TESTS)
TABLE 47 TUBERCULOSIS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 48 TUBERCULOSIS MARKET, BY REGION, 2021-2028 (MILLION TESTS)
TABLE 49 INFLUENZA MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 50 INFLUENZA MARKET, BY REGION, 2021-2028 (MILLION TESTS)
TABLE 51 OTHER INFECTIOUS DISEASES MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 52 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 53 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY REGION, 2021-2028 (USD MILLION)
TABLE 54 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 55 BREAST CANCER MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 56 COLORECTAL CANCER MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 57 LUNG CANCER MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 58 PROSTATE CANCER MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 59 GLOBAL CANCER INCIDENCE, 2020
TABLE 60 OTHER CANCERS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 61 MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2021-2028 (USD MILLION)
TABLE 62 MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
TABLE 63 MOLECULAR DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2021-2028 (USD MILLION)
TABLE 64 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 65 MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021-2028 (USD MILLION)
TABLE 66 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021-2028 (USD MILLION)
TABLE 67 MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)
TABLE 68 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 69 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 70 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 71 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 72 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 73 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 74 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 75 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 76 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 77 US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 78 US: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 79 US: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 80 US: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 81 US: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 82 US: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 83 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 84 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 85 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 86 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 87 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 88 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 89 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 90 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 91 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 92 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 93 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 94 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 95 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 96 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 97 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 98 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 99 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 100 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 101 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 102 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 103 UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 104 UK: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 105 UK: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 106 UK: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 107 UK: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 108 UK: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 109 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 110 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 111 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 112 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 113 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 114 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 115 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 116 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 117 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 118 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 119 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 120 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 121 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 122 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 123 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 124 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 125 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 126 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 127 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 128 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 129 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 130 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 131 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 132 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 133 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 134 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 135 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 136 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 137 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 138 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 139 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 140 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 141 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 142 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 143 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 144 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 145 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 146 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 147 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 148 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 149 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 150 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 151 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 152 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 153 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 154 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 155 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 156 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 157 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 158 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 159 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 160 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 161 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 162 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 163 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 164 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 165 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 166 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 167 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 168 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 169 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 170 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 171 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 172 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 173 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 174 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 175 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 176 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 177 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 178 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 179 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 180 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 181 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 182 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 183 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 184 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 185 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 186 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 187 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 188 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 189 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 190 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 191 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 192 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 193 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 194 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 195 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 196 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 197 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 198 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 199 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 200 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 201 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 202 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 203 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 204 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 205 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 206 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 207 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 208 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
TABLE 209 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 210 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MOLECULAR DIAGNOSTIC MANUFACTURING COMPANIES
TABLE 211 MOLECULAR DIAGNOSTICS MARKET: DEGREE OF COMPETITION
TABLE 212 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR PCR, BY KEY PLAYER, 2022
TABLE 213 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR DNA SEQUENCING AND NGS, BY KEY PLAYER, 2022
TABLE 214 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR INAAT, BY KEY PLAYER, 2022
TABLE 215 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR ISH, BY KEY PLAYER, 2022
TABLE 216 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR INFECTIOUS DISEASES, BY KEY PLAYER, 2022
TABLE 217 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 218 COMPANY PRODUCT & SERVICE FOOTPRINT
TABLE 219 COMPANY REGIONAL FOOTPRINT
TABLE 220 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
TABLE 221 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
TABLE 222 KEY DEALS
TABLE 223 DANAHER: COMPANY OVERVIEW
TABLE 224 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
TABLE 225 HOLOGIC, INC.: COMPANY OVERVIEW
TABLE 226 ILLUMINA, INC.: COMPANY OVERVIEW
TABLE 227 ABBOTT LABORATORIES: COMPANY OVERVIEW
TABLE 228 BIOMÉRIEUX: COMPANY OVERVIEW
TABLE 229 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 230 QIAGEN: COMPANY OVERVIEW
TABLE 231 REVVITY: COMPANY OVERVIEW
TABLE 232 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
TABLE 233 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
TABLE 234 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW
TABLE 235 VELA DIAGNOSTICS: COMPANY OVERVIEW
TABLE 236 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW
TABLE 237 ELITECHGROUP: COMPANY OVERVIEW
TABLE 238 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW
TABLE 239 SAVYON DIAGNOSTICS: COMPANY OVERVIEW
TABLE 240 ABACUS DIAGNOSTICA OY.: COMPANY OVERVIEW
TABLE 241 GENEOMBIO TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW
LIST OF FIGURES (48 FIGURES)
FIGURE 1 MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
FIGURE 5 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
FIGURE 6 MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
FIGURE 7 DATA TRIANGULATION METHODOLOGY
FIGURE 8 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
FIGURE 9 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 10 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 11 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 12 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 13 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 14 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
FIGURE 15 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND RISING INCIDENCE OF CANCER TO SUPPORT MARKET
FIGURE 16 REAGENTS & KITS TO DOMINATE MOLECULAR DIAGNOSTICS MARKET IN 2028
FIGURE 17 LAB TESTS TO COMMAND GREATER MARKET SHARE IN 2028
FIGURE 18 BLOOD, SERUM, AND PLASMA SEGMENT TO DOMINATE MARKET DURING STUDY PERIOD
FIGURE 19 PCR SEGMENT TO DOMINATE MOLECULAR DIAGNOSTICS MARKET DURING FORECAST PERIOD
FIGURE 20 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO DOMINATE MARKET IN 2028
FIGURE 21 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MOLECULAR DIAGNOSTICS MARKET DURING STUDY PERIOD
FIGURE 23 MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 24 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2013-DECEMBER 2022)
FIGURE 25 VALUE CHAIN ANALYSIS OF MOLECULAR DIAGNOSTICS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
FIGURE 26 MOLECULAR DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 27 MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM/MARKET MAP ANALYSIS
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS
FIGURE 29 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS
FIGURE 30 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR IN INDIA
FIGURE 31 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
FIGURE 32 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
FIGURE 33 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
FIGURE 34 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022)
FIGURE 35 MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
FIGURE 36 MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
FIGURE 37 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
FIGURE 38 DANAHER: COMPANY SNAPSHOT (2022)
FIGURE 39 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
FIGURE 40 HOLOGIC, INC.: COMPANY SNAPSHOT (2022)
FIGURE 41 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
FIGURE 42 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
FIGURE 43 BIOMÉRIEUX: COMPANY SNAPSHOT (2022)
FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2022)
FIGURE 46 REVVITY: COMPANY SNAPSHOT (2022)
FIGURE 47 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2022)
FIGURE 48 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
